ECE2020 Audio ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (285 abstracts)
1 Hospital Universitario Puerta del Mar, Endocrinología y Nutrición, Cadiz, Spain; 2Royal College of Surgeons in Ireland, Centre for Systems Medicine, Department of Physiology and Medical Physics, Dublin, Ireland; 3Mater Misericordiae University Hospital, Endocrinology, Dublin, Ireland
Gestational Diabetes Mellitus (GDM) is characterized by insulin resistance accompanied byreduced beta-cell compensation to increased insulin demand, typically observed in the secondand third trimester and associated with adverse pregnancy outcomes. There is a need for abiomarker that can accurately diagnose GDM, predict onset and accurately monitor status, reducing foetal-maternal morbidity and mortality risks. To this end, circulating microRNAs(miRNAs) present themselves as promising candidates, stably expressed in serum and knownto play crucial roles in regulation of glucose metabolism. We analyzed circulating miRNAprofiles in a cohort of GDM patients (n = 31) and nondiabetic controls (n = 29) during the thirdtrimester for miRNA associated with insulin-secretory defects and glucose homeostasis. Weidentified miR-330-3p as being significantly upregulated in GDM compared to nondiabeticcontrols. Furthermore, increased levels of miR-330-3p were associated with better responseto treatment (diet vs insulin), with lower levels associated with exogenous insulin requirement. We observed miR-330-3p to be significantly related to the percentage of caesarean deliveries, with miR-330-3p expression significantly higher in spontaneously delivered GDM patients. These results suggest miR-330-3p may help direct personalized therapy in GDM, predictdiabetic outcome and/or severity and progression, and further discriminate the diagnosticcriteria employed in GDM diagnosis during pregnancy.